Impact of protein kinase CK2 downregulation and inhibition on oncomir clusters 17 ~ 92 and 106b ~ 25 in prostate, breast, and head and neck cancers
Targeting CK2 for the development of new cancer therapies is under active investigation in many laboratories and pharmaceutical companies. Our data suggest a new role for CK2 in cell signaling and survival in multiple cancer types through maintenance of miR-17 ~ 92 and 106b ~ 25 biogenesis.
Authors
- Khalil Ahmed (ORCID: https://orcid.org/0000-0003-4531-6837)
- Betsy T. Kren
- Christine Henzler (ORCID: https://orcid.org/0000-0003-4566-2211)
- Janeen H. Trembley (ORCID: https://orcid.org/0000-0003-3597-2611)
Institutions
- University of Minnesota (US)
- Minneapolis VA Health Care System (US)
- University of Minnesota Medical Center (US)
Publication Details
- Journal
- Molecular Medicine
- Published
- 2024-10-11
- DOI
- https://doi.org/10.1186/s10020-024-00937-1
- Citations
- 3
- Primary Topic
- MicroRNA in disease regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.86
Funders
- U.S. Department of Health and Human Services
- U.S. Department of Veterans Affairs
- National Institutes of Health
- National Cancer Institute